Long Covid and Blood Clots

Covid19 infections appear to increase the risk of blood clots. Such blood clots could result in strokes, coronary heart attacks or even deep vein thrombosis. It has been suggested that blood microclots, as well as clotting abnormalities, are relatively common in patients with Long Covid (https://www.theguardian.com/society/2022/jun/27/possible-link-between-blood-clots-and-covid-symptoms-investigated). The University College of London's Stimulate ICP study will investigate the potential link between blood clots and Long Covid. This will, presumably be a double blind study (one where neither the patients nor the scientists know which treatments patients receive, until the end of treatment). The recruited 4,500 Long Covid patients, will be allocated to 4 groups. They will be respectively given:- a) normal care (with placebo 'medication'?); b) anti-histamine; c) an anti-inflammatory or d) an anti-clotting drug. Patients, in this trial, will receive their treatments for 3 months. The effects of the 4 treatments on Long Covid symptoms (especially chronic fatigue) will then be assessed. The study would have to be double blind, as will rely on self-reported assessments e.g.'fatigue'. Hopefully, the data will enable the researchers to establish whether blood 'thinners' can be safely used to improve Long Covid symptoms. Anti-clotting drugs might cause inappropriate bleeding in some patients.